Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points.

Oral roflumilast showed significant efficacy in reducing psoriasis severity, with 63% achieving PASI less than 5 by week 24. The study reported mild gastrointestinal symptoms but no serious ...

Roflumilast is a highly selective phosphodiesterase (PDE)-4 inhibitor with significant pulmonary and systemic anti-inflammatory effects. Roflumilast has a pharmacokinetic profile that permits once ...